標(biāo)題: Titlebook: Drugs between Research and Regulations; Proceedings of the 5 C. Steichele (Medizinischer Direktor),U. Abshagen Conference proceedings 1985 [打印本頁] 作者: 無感覺 時(shí)間: 2025-3-21 17:33
書目名稱Drugs between Research and Regulations影響因子(影響力)
書目名稱Drugs between Research and Regulations影響因子(影響力)學(xué)科排名
書目名稱Drugs between Research and Regulations網(wǎng)絡(luò)公開度
書目名稱Drugs between Research and Regulations網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Drugs between Research and Regulations被引頻次
書目名稱Drugs between Research and Regulations被引頻次學(xué)科排名
書目名稱Drugs between Research and Regulations年度引用
書目名稱Drugs between Research and Regulations年度引用學(xué)科排名
書目名稱Drugs between Research and Regulations讀者反饋
書目名稱Drugs between Research and Regulations讀者反饋學(xué)科排名
作者: 合同 時(shí)間: 2025-3-21 21:49 作者: 過分自信 時(shí)間: 2025-3-22 02:17 作者: inculpate 時(shí)間: 2025-3-22 08:09 作者: Obligatory 時(shí)間: 2025-3-22 09:30
els in 1978 (,Pharmaceutical Medicine - the Future‘) and Paris in 1981 (‘Drug Safety -;- Progress and Controversies‘). This 5th meeting discussed improvements in drug development and application and examined the impact of regulatory activities.978-3-642-54132-2978-3-642-54130-8作者: CONE 時(shí)間: 2025-3-22 14:19 作者: CONE 時(shí)間: 2025-3-22 17:33 作者: Cytokines 時(shí)間: 2025-3-23 00:03 作者: LANCE 時(shí)間: 2025-3-23 03:57
The need of clinical drug trials in children be responsible for this “therapeutic orphan” situation of the child and these include the ignorance and indifference of drug manufacturers and pediatricians, a negative public attitude towards clinical research in general and an uncertainty in the legal and ethical requirements for drug testing in 作者: 不出名 時(shí)間: 2025-3-23 07:43
Outro,cceed, now and again, in thwarting their deliberations and obscuring their aims. The issue of Guidelines for the Clinical Investigation of Drugs is a case in point. They are hailed by some and condemned by others and nine tenths of the problem is that the one party really has little idea what the other party is talking about.作者: fledged 時(shí)間: 2025-3-23 12:24
https://doi.org/10.1007/978-1-4842-4950-5sons and, at least in Italy, the law prevent the GP from taking a direct part in the first phases of clinical research; on the other hand, even after the introduction of a medicine onto the market, the general practitioner’s involvement is considered to be that of prescription rather than evaluation.作者: 勾引 時(shí)間: 2025-3-23 16:21
Installing Third-Party Libraries,linical trials, with special reference to drug evaluation after marketing (Phase IV). I shall deal with it from the vantage of a decade and a half of consultation work in this area, especially with the Drug Epidemiology Unit of Boston University School of Medicine.作者: Amylase 時(shí)間: 2025-3-23 19:48
Clinical guidelines — a help or a hindrance?cceed, now and again, in thwarting their deliberations and obscuring their aims. The issue of Guidelines for the Clinical Investigation of Drugs is a case in point. They are hailed by some and condemned by others and nine tenths of the problem is that the one party really has little idea what the other party is talking about.作者: Aspiration 時(shí)間: 2025-3-23 23:51 作者: FLIP 時(shí)間: 2025-3-24 03:04
Alternatives to clinical trials in post-marketing research on drug effectslinical trials, with special reference to drug evaluation after marketing (Phase IV). I shall deal with it from the vantage of a decade and a half of consultation work in this area, especially with the Drug Epidemiology Unit of Boston University School of Medicine.作者: MELON 時(shí)間: 2025-3-24 07:28
Managing Device Drivers and PC ResourcesRisk: benefit decision making lies at the heart of modern therapeutics, and it is possible to distinguish between four categories of problem.作者: SLAY 時(shí)間: 2025-3-24 10:44 作者: 翅膀拍動(dòng) 時(shí)間: 2025-3-24 14:49
The organisation of long-term intervention and prevention studiesRisk: benefit decision making lies at the heart of modern therapeutics, and it is possible to distinguish between four categories of problem.作者: 反對(duì) 時(shí)間: 2025-3-24 20:33 作者: 保留 時(shí)間: 2025-3-25 00:30 作者: MOCK 時(shí)間: 2025-3-25 05:20 作者: duplicate 時(shí)間: 2025-3-25 09:37
http://image.papertrans.cn/e/image/283216.jpg作者: Aerophagia 時(shí)間: 2025-3-25 12:22
My Story, humans are exposed for an extended period of time. Thus, the intention was not to study the acute toxic reactions, but rather the slowly developing lesions related to organ-directed toxicity, accumulation of the test substance or its metabolites in certain organs, functional and structural changes 作者: 商品 時(shí)間: 2025-3-25 18:30 作者: 只有 時(shí)間: 2025-3-25 21:07 作者: Alveoli 時(shí)間: 2025-3-26 00:43
Writing,d ., i.e. in whole rodent and nonrodent animals. Certain rules and regulations exist that govern the form of performance of chronic toxicity testing for different sectors of our chemical world, for example, OECD regulations for testing of chemicals, EEC and FDA regulations for testing pharmaceutical作者: commonsense 時(shí)間: 2025-3-26 07:20 作者: airborne 時(shí)間: 2025-3-26 10:12
Outro,cceed, now and again, in thwarting their deliberations and obscuring their aims. The issue of Guidelines for the Clinical Investigation of Drugs is a case in point. They are hailed by some and condemned by others and nine tenths of the problem is that the one party really has little idea what the ot作者: 收藏品 時(shí)間: 2025-3-26 13:37 作者: 極微小 時(shí)間: 2025-3-26 20:34 作者: Focus-Words 時(shí)間: 2025-3-26 21:58 作者: 水汽 時(shí)間: 2025-3-27 01:07
Networks and Internet Connectionsdress with the title: “The Field Trial: some thoughts on the indispensable ordeal” (Fredrickson 1968). This was when the era of the large intervention studies started and trials like MRFIT were being planned. The sober words “indispensable” and “ordeal” which Fredrickson advisedly used, reflect the 作者: 生命 時(shí)間: 2025-3-27 06:46 作者: inconceivable 時(shí)間: 2025-3-27 11:07
Dealing with Common Windows Annoyancesinical colleagues every day. Pressures on limited resources, even in diseases with high incidence or morbidity, have long made the multicentre trial an unwelcome methodological fixture. A great deal more could still be said about the strengths and weaknesses of the techniques used to make the infere作者: MIR 時(shí)間: 2025-3-27 15:04 作者: Ondines-curse 時(shí)間: 2025-3-27 19:44 作者: Postmenopause 時(shí)間: 2025-3-27 23:24 作者: ENACT 時(shí)間: 2025-3-28 02:11
https://doi.org/10.1007/978-1-4842-9348-5vailing in pediatric research. Of course, methodological difficulties do exist, but experience shows that they can usually be overcome: the protocol can be especially designed for rapidly developing individuals and there are virtually unlimited possibilities to develop improved measuring techniques 作者: 同義聯(lián)想法 時(shí)間: 2025-3-28 08:15
My Story,mple hyperplasia to benign and malignant tumors, metabolic disturbances such as fatty infiltration, glycogenosis and phospholipidosis, organ degenerations, e.g. atrophy, swelling and necrosis, and reactive responses such as inflammation, fibrosis and cirrhosis.作者: 正論 時(shí)間: 2025-3-28 13:07 作者: infringe 時(shí)間: 2025-3-28 16:18 作者: Graves’-disease 時(shí)間: 2025-3-28 22:25
Chronic toxicity tests, current problems and possible solutionsmple hyperplasia to benign and malignant tumors, metabolic disturbances such as fatty infiltration, glycogenosis and phospholipidosis, organ degenerations, e.g. atrophy, swelling and necrosis, and reactive responses such as inflammation, fibrosis and cirrhosis.作者: 性學(xué)院 時(shí)間: 2025-3-29 02:35
What good are clinical trials?d each one involves patient care, the time of physicians and staff. Many require large amounts of money and other resources and therefore to make a judgement of how good they are will always be a question of balance, not only between benefit and risk but also between value in its widest sense and the resources expended.作者: syncope 時(shí)間: 2025-3-29 05:34 作者: Oafishness 時(shí)間: 2025-3-29 10:30
Alternatives to chronic toxicity studiesor different sectors of our chemical world, for example, OECD regulations for testing of chemicals, EEC and FDA regulations for testing pharmaceutical substances. The requirements differ in regard to the number and selection of species, number of animals per dose group and experiment, modes of application and duration of experiment.作者: Lobotomy 時(shí)間: 2025-3-29 12:20 作者: dry-eye 時(shí)間: 2025-3-29 18:08 作者: 嚴(yán)厲譴責(zé) 時(shí)間: 2025-3-29 22:52 作者: WAG 時(shí)間: 2025-3-30 02:52 作者: 疏遠(yuǎn)天際 時(shí)間: 2025-3-30 04:07 作者: fledged 時(shí)間: 2025-3-30 09:15 作者: deface 時(shí)間: 2025-3-30 15:04
Extending Istio with WebAssembly,t of the therapy to the patient. A clinical trial can be contrasted with an observational study where one undertakes a retrospective record review in an attempt to determine the benefit of therapy which has been administered to patients. In general, the use of observational studies to establish the value of therapies is not reliable.作者: MAZE 時(shí)間: 2025-3-30 18:40
The role of carcinogenicity studies in risk assessments opened the view to possible long-term consequences of certain forms of chemotherapy. Furthermore, for drugs in general which are intended for longer-term use, the question of carcinogenicity has become, from the regulatory point of view, most decisive for the fate of a new product.作者: 神經(jīng) 時(shí)間: 2025-3-30 22:56 作者: reaching 時(shí)間: 2025-3-31 01:31 作者: 輕快帶來危險(xiǎn) 時(shí)間: 2025-3-31 06:05
https://doi.org/10.1007/978-1-4842-9348-5f pharmacological studies possible within the set ethical limits. These limits themselves, however, are not directly related to the progress in medical research. They are determined by public opinion in a given country at a given time and are not likely to change rapidly.作者: 開始從未 時(shí)間: 2025-3-31 09:54 作者: 遵循的規(guī)范 時(shí)間: 2025-3-31 14:47
Rauwolfia derivatives and breast cancer: how do we know when we have the answers?ugh it has some properties in common with those of the multicentre trial, seems to have received rather less attention or even to have been almost entirely neglected by some of those whom it most concerns is the combination of information from studies that are spread out not only in space but also in time.作者: sed-rate 時(shí)間: 2025-3-31 20:13 作者: 伙伴 時(shí)間: 2025-4-1 01:02
Conference proceedings 1985of a gathering which so clearly bore his imprint as Chairman of the Scientific Program Committee. His sudden passing away is deeply regretted by all of us: organizers, speakers and participants. We greatly respect him for his exceptional abilities, his impact on science and his qualities as a human 作者: 哥哥噴涌而出 時(shí)間: 2025-4-1 05:06
Chronic toxicity tests, current problems and possible solutions humans are exposed for an extended period of time. Thus, the intention was not to study the acute toxic reactions, but rather the slowly developing lesions related to organ-directed toxicity, accumulation of the test substance or its metabolites in certain organs, functional and structural changes
